Navigation Links
Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule

Oramed is one of 60 Companies Selected to Participate at the "Facing

Tomorrow" Conference Marking the Country's 60th Birthday

JERUSALEM, Israel, May 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP), a developer of oral delivery systems, has been selected for the first annual Presidential conference, "Facing Tomorrow," as one of the 60 "enterprises of tomorrow" representing the future face of Israel. The monumental event is being held to mark the country's sixtieth birthday.

Additionally, Oramed was one of six companies chosen to be featured in a video presentation at the conference's opening event. The conference will be attended by global political and business leaders, including Israeli Prime Minister Ehud Olmert, President George W. Bush and Google founder Sergey Brin.

"The selection of Oramed as one of the companies to change the face of tomorrow is a great honor," said Nadav Kidron, CEO of Oramed Pharmaceuticals. "Being chosen for the conference illustrates the potential of our technology to make a significant difference for millions of diabetics around the world."

The conference will be held May 13-15 at the Jerusalem International Convention Center.

For more information on the conference, please visit the conference's website at:

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is an Israeli-based company focused on the development of oral delivery solutions based on proprietary technology. Oramed is currently developing an orally ingestible insulin capsule for the treatment of diabetes. The oral administration of insulin is more physiological than the current delivery method, mimicking the natural path of insulin throughout the body. The company is also pursuing the development of oral delivery solutions for drugs and vaccines presently delivered via injection.

For more information, please visit our website at:

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Tara Horn

Cell: +972-54-33-44-318

Office: +972-2-566-0001


Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-46-76-950

Office: +972-2-589-2003


SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Fraunhofer and Boston University Hosted Prestigious SME Tour
2. Prestigious Scientific Leaders Join InterWest Advisory Committee
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. Launch of New, Prestigious Infertility and Gynaecology Research GrAnt (FRIGGA)
5. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
6. Research by Case Western Reserve University, VA earns cover of prestigious science publication
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
9. Prestigious Bioethics Award for Scholar from Mexico
10. Physics professor lauded for NSF efforts with prestigious award
11. Physics professor lauded for NSF efforts with prestigious award
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... But unless it is bound to proteins, copper is also toxic to cells. ... at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Paris , ... --> Paris , qui s,est tenu ... le leader de l,innovation biométrique, a inventé le premier ... empreintes sur la même surface de balayage. Jusqu,ici, deux ... pour les empreintes digitales. Désormais, un seul scanner est ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):